Janssen loses appeal over Stelara patent, Dutch court backs Samsung Bioepis
Janssen Biotech has lost its appeal against Samsung Bioepis in a Dutch patent dispute over biosimilar production of an active ingredient in a drug used to treat Crohn’s disease and others....To view the full article, register now.
Already a subscriber? Click here to view full article